AlphaTON Capital Corp Stock Price, News & Analysis

AlphaTON Capital Corp (Nasdaq: ATON) and its oncology subsidiary Cyncado Therapeutics announced an AACR abstract (presented Oct 25, 2025) reporting that selective A2B (ADORA2B) receptor inhibition reduced adenosine-mediated PD-L1 expression in a human epithelioid mesothelioma cell line, linked to decreased pCREB. In an immunocompetent mesothelioma model, the investigational agent TT-4 as monotherapy outperformed anti-PD-1, and the TT-4 + anti-PD-1 combination showed significantly greater anti-tumor activity and increased T-cell infiltration. Additional data will be shown at the poster session in Boston on Saturday, October 25, 2025, 12:30–4:00 PM EDT.

AlphaTON Capital (NASDAQ: ATON) announced that Enzo Villani, Chief Investment Officer, will speak at the 10th Anniversary IASC World Changers Summit on October 20, 2025 at the Casina Pio IV in Vatican City.

Villani will deliver a 10-minute address on the intersection of ethics, innovation, and digital transformation, drawing on two decades of experience in finance, blockchain, and global impact. The Summit gathers global thought leaders to discuss ethical innovation, cooperation across nations and faiths, and sustainable, purpose-driven technology.

AlphaTON Capital (Nasdaq: ATON) sponsored and hosted the TOKEN2049 Singapore “Origins” Hackathon at Marina Bay Sands on October 15, 2025, awarding a US$25,000 prize pool paid in TON to global developers focused on AI, payments, and infrastructure.

Track leads and mentors selected winners across three tracks: AI (IntentHub 1st), Payments (Telepay 1st), and Infrastructure (Encrypted Prediction-Market Seeding 1st). AlphaTON said it will continue a global HackATON series to support TON builders with capital, mentorship, and go-to-market routes.

AlphaTON Capital (Nasdaq: ATON) CEO Brittany Kaiser will appear with Anthony Scaramucci on Schwab Network’s Trading 360 with Marley Kayden on October 14, 2025 at 11:30 a.m. ET. The live segment will discuss the evolving role of digital assets in modern finance and AlphaTON’s approach to funding cancer research using blockchain-based asset tokenization. The company describes tokenized assets as a way to connect investors and researchers and create new funding pathways. Viewers can watch the live discussion on Schwab Network.

AlphaTON Capital (Nasdaq: ATON) announced a strategic partnership with Morpheus AI on October 13, 2025 to make Morpheus the preferred AI infrastructure provider for AlphaTON portfolio companies building on TON and Telegram.

The MOU covers decentralized inference, a tools marketplace, and decentralized storage to accelerate agentic AI development and reduce integration time for AI agents. The deal highlights use of $MOR tokens within the ecosystem and a knowledge-sharing collaboration between the two firms.

AlphaTON Capital (NASDAQ: ATON) announced Nasdaq publicly congratulated the company for pioneering a blockchain-based cancer research tokenization initiative; the recognition was displayed on the Nasdaq Tower in Times Square on October 10, 2025. AlphaTON is partnering with Cyncado Therapeutics to fund oncology programs via tokenized assets, aiming to increase liquidity, improve transparency of fund allocation, lower investor minimums, and accelerate R&D timelines. The company said the model helped advance multiple research programs and that it plans to expand tokenization to more therapeutic areas and institutional partners.

AlphaTON Capital (NASDAQ: ATON) announced that CIO and Executive Chairman Enzo Villani was interviewed live at Nasdaq MarketSite with IPO Edge on October 2, 2025. The fireside chat covered the TON blockchain, Telegram ecosystem growth, platform security, communication privacy, and AlphaTON's institutional treasury strategy.

AlphaTON described a three-pillar approach: direct TON acquisition and yield activities, validator and staking operations, and incubating Telegram mini apps. The company highlighted connections to industry partners and noted Telegram's reach of over one billion monthly active users.

AlphaTON Capital (NASDAQ: ATON) and its oncology subsidiary Cyncado Therapeutics announced a non-binding LOI to evaluate tokenization of the economic rights for TT-4, an oral A2B receptor antagonist targeting mesothelioma. Cyncado is in final start-up preparations for TT-4 with first-patient dosing targeted for Q1 2026 under its existing FDA-cleared TT-10-101 protocol, followed by a mesothelioma-focused study at major U.S. cancer centers. Preclinical results cited include >90% tumor growth inhibition, 60% complete responses with anti-PD-1 combination, and >90-day survival in combination groups. The LOI is exploratory and non-binding; any tokenization would preserve traditional licensing and financing pathways and require board approval and regulatory clearance.

Health In Tech (NASDAQ: HIT) has signed a strategic Letter of Intent (LOI) with AlphaTON Capital (NASDAQ: ATON) to develop HITChain, a blockchain-powered healthcare insurance claims processing platform built on The Open Network (TON). The platform aims to address inefficiencies in the $4.5 trillion U.S. healthcare market, where claims administration currently costs over $300 billion annually.

The collaboration combines Health In Tech's insurance expertise with AlphaTON's blockchain infrastructure to create an immutable, transparent claims ecosystem. Health In Tech will provide insurance domain expertise and established industry relationships, while AlphaTON will contribute blockchain development expertise, smart contract architecture, and security protocols.